1-7 of 7
Jyothis T. George
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial

Vlado Perkovic, Robert Toto, Mark E. Cooper, Johannes F.E. Mann, Julio Rosenstock, Darren K. McGuire, Steven E. Kahn, Nikolaus Marx, John H. Alexander, Bernard Zinman, Egon Pfarr, Sven Schnaidt, Thomas Meinicke, Maximillian von Eynatten, Jyothis T. George, Odd Erik Johansen, Christoph Wanner
Journal: Diabetes Care
Diabetes Care 2020;43(8):1803–1812
https://doi.org/10.2337/dc20-0279
Published: 22 May 2020
View article titled, Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
Open the PDF for Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial in another window
Journal Articles

Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial

Geert Jan Biessels, Chloë Verhagen, Jolien Janssen, Esther van den Berg, Bernard Zinman, Julio Rosenstock, Jyothis T. George, Anna Passera, Sven Schnaidt, Odd Erik Johansen
Journal: Diabetes Care
Diabetes Care 2019;42(10):1930–1938
https://doi.org/10.2337/dc19-0783
Published: 09 August 2019
View article titled, Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial
Open the PDF for Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial in another window
Includes: Supplementary data
Journal Articles

Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes

Bruce A. Perkins, Julio Rosenstock, Jay S. Skyler, Lori M. Laffel, David Z. Cherney, Chantal Mathieu, Christianne Pang, Richard Wood, Ona Kinduryte, Jyothis T. George, Jan Marquard, Nima Soleymanlou
Journal: Diabetes Care
Diabetes Care 2019;42(9):1716–1723
https://doi.org/10.2337/dc19-0548
Published: 11 July 2019
View article titled, Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes
Open the PDF for Exploring Patient Preferences for Adjunct-to-Insulin Therapy in Type 1 Diabetes in another window
Journal Articles

Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial

Silvio E. Inzucchi, Christoph Wanner, Uwe Hehnke, Isabella Zwiener, Stefan Kaspers, Douglas Clark, Jyothis T. George, Bernard Zinman
Journal: Diabetes Care
Diabetes Care 2019;42(4):e53–e55
https://doi.org/10.2337/dc18-1355
Published: 31 January 2019
View article titled, Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial
Open the PDF for Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial in another window
Journal Articles

Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial

Subodh Verma, C. David Mazer, Deepak L. Bhatt, Satish R. Raj, Andrew T. Yan, Atul Verma, Ele Ferrannini, Gudrun Simons, Jisoo Lee, Bernard Zinman, Jyothis T. George, David Fitchett
Journal: Diabetes Care
Diabetes Care 2019;42(3):e42–e44
https://doi.org/10.2337/dc18-1959
Published: 23 January 2019
View article titled, Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial
Open the PDF for Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial in another window
Journal Articles

How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial

Silvio E. Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T. George, Stefan Hantel, Erich Bluhmki, John M. Lachin
Journal: Diabetes Care
Diabetes Care 2018;41(2):356–363
https://doi.org/10.2337/dc17-1096
Published: 04 December 2017
View article titled, How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Open the PDF for How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial in another window
Includes: Supplementary data
Journal Articles

Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?

Nikolaus Marx, Darren K. McGuire, Vlado Perkovic, Hans-Juergen Woerle, Uli C. Broedl, Maximilian von Eynatten, Jyothis T. George, Julio Rosenstock
Journal: Diabetes Care
Diabetes Care 2017;40(9):1144–1151
https://doi.org/10.2337/dc17-0068
Published: 14 August 2017
View article titled, Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point?
Open the PDF for Composite Primary End Points in Cardiovascular Outcomes Trials Involving Type 2 Diabetes Patients: Should Unstable Angina Be Included in the Primary End Point? in another window